New Phase 3 trial: A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer — CSPC Megalith Biopharmaceutical Co.,Ltd.

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-19 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES0

STORY SIZESTANDALONE

FIRST SEEN2026-10-19 12:00 UTC

LAST UPDATE2026-10-19 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.; Status: Not Yet Recruiting; Conditions: Triple Negative Breast Cancer; Interventions: Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）; Enrollment: 550 (estimated); First posted: 2026-10-19; NCT: NCT07879911

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-19 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
AMD filed 4 on 2026-10-192026-10-19 00:00 UTC

←INFERENCEfilings generate company commentary
MA filed 4 on 2026-10-192026-10-19 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.